Merck halts small cell lung cancer immunotherapy drug trial
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated.
Switzerland’s Novartis AG has received accelerated approval from the USFDA for its drug to reduce elevated levels of proteins in the urine of.
Danish biotechnology company, Pharmacosmos A/S will buy US-based G1 Therapeutics Inc., for $405 million to expand its global commercial portfolio in haematology.
The WHO’s event-based surveillance system has reported that at least 40 athletes participating in the Olympic Games in France had tested positive for.
Scientists at Northwestern University's Simpson Querrey Institute for BioNanotechnology have invented a bioactive material to successfully regenerate cartilage in the knee joints of.
Servier Pharmaceuticals, the US arm of a French pharmaceutical company, got approval from the US drug regulator for a once-daily pill to treat.
Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.
A family of antimicrobial compounds can neutralise necrotising fasciitis, a deadly bacterial skin infection that is also known as flesh-eating disease, when tested.
HQ Team August 6, 2024: A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the.
Contineum Therapeutics, Inc., a US San Diego-headquartered biopharmaceutical company’s trial drug may reverse multiple sclerosis damage by potentially restoring movement and function.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com